ArticleThe lancet. Diabetes & endocrinology2017
Sacubitril/valsartan in PARADIGM-HF.
Article in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective.Journal of cellular and molecular medicine · 2024Review
- Article
- Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena.Journal of diabetes · 2023Review
- Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension.Circulation reports · 2022Article
- Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice withAmerican journal of physiology. Endocrinology and metabolism · 2022Article
- Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction.Frontiers in endocrinology · 2022Article
- Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.Therapeutic advances in endocrinology and metabolism · 2020Review
- Neprilysin inhibition: a new therapeutic option for type 2 diabetes?Diabetologia · 2019Review
- Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Article
- Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.Islets · 2018Article
Corrections and comments
- Expression of concern · 2019-02-20Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Objections by Third Party ·
- Commented on by
- Comment on
- Erratum issued
- Expression of concern
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28645438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.